November 25, 2020 -- Celltrion has enrolled patients with mild to moderate symptoms of SARS-CoV-2 infection in a phase II clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment.
The company enrolled 327 people in the randomized, double-blind, placebo-controlled and parallel-group trial designed to evaluate the treatment's efficacy and safety. In addition, Celltrion plans to initiate a phase III clinical trial in more than 10 countries to obtain more safety and efficacy results of CT-P59.
The company expects to submit an emergency use authorization to the Korean Ministry of Food and Drug Safety once the results from the trial are revealed.
Celltrion is also working to increase its manufacturing capabilities to meet the need for anti-COVID-19 monoclonal antibody treatments. The company hopes to potentially deliver as many as 2 million doses of the treatment in 2021.